ROTAVIRUS INFECTION IN NEWBORNS CHILDREN: CLINICAL PERFORMANCE, TREATMENT AND PROPHYLAXY, 2004
TUNDA I. P.
Health Care Practice has proposed effective preventive measures based on the results of clinical and virological studies and determining RVI leading risk factors in infants.
In the practice of maternity and neonatology departments, specialized clinical virological and microbiological monitoring of RVI in newborns has been offered for early diagnosis and prevention of nosocomial RVI.
In complex care unit optimum schemes and methods of administration of recombinant interferon – Laferon in the dose of 50-100,000 IU / kg 2 times a day, in enemas, within 3-5 days has been offered; Enterosgel in the dose of 5 g / kg 3 times a day orally for 5 days. To correct microflora, multyprobiotic Symbiter was applied in RVI treatment in 0.5 dose twice a day, orally, for 10 days.
THE MANAGEMENT OF ACUTE GASTROENTERITIS IN CHILDREN, 2012
M. Plescik-Lech, R. Shamir, A. Guarino, H. Szajewska
Efforts to improve the taste and/or efficacy of oral rehydration solution (ORS) continue, and some interventions are promising. While standard (over 24 h) nasogastric rehydration is still being used, new evidence confirms that
rapid (over 4 h) rehydration is also effective. For intravenous rehydration, new evidence is available regarding rapid or ultrarapid and large-volume vs. standard-volume rehydration; as the new evidence is not consistent, until
more data are available, the administration of 20 mL/kg seems appropriate.
Convincing evidence has accumulated showing that ondansetron reduces the risk for vomiting; however, a clearance on safety in children is needed. New evidence has reconfirmed that in Europe, where zinc deficiency is rare, there is no benefit from the use of zinc. New data, although mainly from outside of Europe, have reconfirmed that either smectite or racecadotril is an effective adjunctive therapy to oral rehydration. There is a clear effect of using certain probiotics, such as Lactobacillus GG or S. boulardii.
APPLICATION OF ENTEROSGEL IN COMPLEX TREATMENT OF NEONATES WITH PERINATAL PATHOLOGY, 2007
Mizgina T.I., Gurobska L.І., Goryachevska Т.М., Krykotenko L.V.
The article discusses the best practice of Enterosgel application in infants with perinatal pathology. High efficiency of Enterosgel has been shown in complex therapy of patients with neonatal hyperbilirubinemia, intestinal dysbiosis and other pathologies. Enterosgel has practically no side effects and is easy to use, being tolerated by the infants; it can also be used for fast and effective non-invasive detoxification.
EFFICIENCY OF ENTEROSGEL IN CORRECTION OF SYSTEMIC ENDOTOXEMIA IN CHILDREN WITH ATOPIC DERMATITIS, 2016
T.G. Malanicheva, B.A. Shamov
Endotoxin aggression is developed with the expressed release of endotoxin (ET) in the bloodstream on the background of insufficient activity of excretory systems and is qualified as a universal mechanism involved in the pathogenesis of many infectious and non-infectious diseases . Systemic endotoxemia can develop as a result of both inactive intestinal microbiota, constant permeability disorders of the intestinal mucous membranes, and pancreatic insufficiency, biliary duct insufficiency, depression of liver barrier function or reduced portal blood flow, etc . ET presence affects immunocompetent blood cells and is one of the considerable stimulation factors of the immune system. Under physiological conditions, anti-endotoxin antibodies are released in response to ET presence . In pathological endotoxemia a decline of adaptive capacity and body resistance takes place [4, 5]. It is also known that endotoxemia causes cellular hypoxia, metabolic disorders, activation of sympathetic nervous system, complement system, resulting in lysis of leukocytes and platelet aggregation with the release of biologically active substances – kinins, histamine, serotonin, causing “mediator chaos.”
All of the above has allowed us to make an assumption about the importance of systemic endotoxemia and endotoxin aggression in atopic dermatitis (AD) in children.
Objective: to define level of systemic endotoxemia in children with AD and evaluate drug Enterosgel (polymethylsiloxane polyhydrate) in complex therapy of the pathology.
COLLECTION OF RESEARCH PAPERS. ENTEROSGEL RESEARCHES, 2015
Dzyublik I, Shunko Em, Barbova A. Clinical efficacy of Enterosgel in treatment of rotovirus infections in newborns
Gorodetsky, Tebechevsky F Clinical efficacy of Enterosgel in treatment of patients with hepatitis A
Tkachenko E., Avalueva E. The Clinical Efficacy and safety of Enterosgel in the treatment of diarrhoea-dominant irritable bowel syndrome.
Tkachenko E., Avalueva E. The Clinical Efficacy and safety of Enterosgel in the treatment of Helicobacter Pylori – associated chronic gastroduodentis
Astahov V., Gusev V. The Clinical Efficacy and safety of Enterosgel in complex prevention of fetoplacental dysfunction in pregnant women with earlier syphilis
Usenko D., Gorelov A. The Clinical Efficacy of Enterosgel, in treatment of intestinal infections in chidren with atopic dermatitis.
Radchenko V., Seliverstov P. The Clinical Efficacy and safety of Enterosgel in treatment of predialysis Cronic Renal Falure (CRF) patients.
Nakhashova V. The Clinical Efficacy of Enterosgel in treatment of patients with Chronic Pancreatitis
Karlyichuk A., Kulachek F. The Clinical Efficacy of Enterosgel in complex treatment and prophylaxis of post-operative intraperitoneal in complication of acute cholecystitis
Moroz L., Paliy M. Use of enterosorbent Enterosgel in complex therapy of acute viral hepatitis B with concomitant intestinal dysbiosis
Sokolov E., Majev I. Clinical efficacy of Enterosgel in patients with digestive system-relative pathology.
Paliy I., Tchernobroviy V. Clinical efficacy of Enterosgel in complex treatment of intestinal dysbiosis
Yurchenko A., Nikolaev V. Clinical efficacy of Enterosgel in treatment of intoxication and diarrhoea in patients with AIDS during antiretroviral therapy.
COLLECTION OF RESEARCH PAPERS. ALLERGOLOGY, IMMUNOLOGY, DERMATOLOGY: NEW APPROACHES, 2013
J. Bystron: “…the basis of allergy management consists first and foremost of the identification of the causal allergen and the effort aimed at its elimination…”
Nagornaya N.V., Dubovaya A.V. The Detoxifying Potential and Clinical Effectiveness of the Enterosorbent Enterosgel in the Combination Therapy of Various Diseases in Children and Adults
Shamov B.A., Malanicheva T.G. Correction of Systemic Endotoxemia in Children with Atopic Dermatitis
Melnykov O.F., Zabrodska L.V., Tymchenko M.D., Sydorenko T.V., Naumova O.A. A Clinical and Immuno-Allergological Study of the Efficacy of Enterosgel in Food Allergy
Malanicheva T.G., Khaertdinova L.A. Enterosorption in the Treatment of Pediatric Atopic Dermatitis Complicated by Fungal Infection
Baranov A.A, Geppe N.A, Karpushkina A.V. The Efficacy of Enterosgel in the Treatment of Children with Bronchial Asthma and Atopic Dermatitis
J. Bystron. Application of Enterosorption Method with Organosilicon Enterosorbent Enterosgel in the Integrated Treatment of Allergic Diseases
Zaytseva N.V, Aminova A.I., Ustinova O.Yu., Akatova A.A., Luzhetskiy K.P. Asthma Prevention in Children with Recurrent Wheezing Bronchitis Who Have Elevated Levels of Heavy Metals and Aldehydes in the Body
Basieva O.Z., Basiev Z.G. Enterosgel in the Combination Treatment of Atopic Bronchial Asthma
Chorna O.O, Binda T.P. On the Issue of the Treatment of Children with Allergic Diseases
Enterosgel® in Allergology and Dermatology: Posology and Method of Administration
ENTEROSORBENTS THERAPY IN CHILDREN WITH ASTHMA LIVING IN POOR SANITARY CONDITIONS, 2013
Zaytseva N. , Usitnova O.
SUMMARY: According to recent epidemiological and toxicological data, children living in poor sanitary conditions develop abnormal physical characteristics, such as morphological abnormalities and chronic diseases of the Central Nervous System and the respiratory, cardiovascular, musculoskeletal, endocrine and digestive Systems. Among the substances of industrial origin, an important role is played by metals that accumulate in the tissues and organs. The toxic effects are due to the type of metal, its concentration, the concurrence of other pathological factors and the general health conditions (immune reactivity, hypersensitivity, etc.). The study was conducted on 236 children suffering from mild asthma (experimental Group) living in areas close to metallurgical plants. The composition of the air – concerning the percentage of manganese, chrome, lead and nickel – was found to have values at the upper limits of standard. The control Group, homogeneous for age, gender and residential area, consisted of 41 children. In order to reduce the blood concentrations of the considered toxic metals, 4 enterosorbents were tested and prescribed for 2 consecutive weeks of therapy: Enterosgel ®, Polysorb™, Polyphepan, and activated charcoal. – Enterosgel ® – blood tests. Decrease from baseline: Mn = 12%; Ni = 64 %; Pb = 20 %; Cr = 56 %. – Polysorb™ – blood tests. Decrease from baseline: Mn = 24%; Ni = 65%; Pb = 20 %; Cr = 66%. – Polyphepan – blood tests. Decrease from baseline: Mn = 0 %; Ni = 51 %; Pb = 12%; Cr = 61 %. – Activated charcoal – blood tests. Decrease from baseline: Mn = 0 %; Ni = 69 %; Pb = 10 %; Cr = 44%. Data reveal that the use of Enterosgel ® and Polysorb™ for 2 consecutive weeks allows to obtain a significant reduction – compared to the controls – of the amount of Cr and Ni (56-66%) and Mn and Pb (12-24%) in the blood of asthmatic children living in poor sanitary conditions.
The problem of elimination of toxic substances from the body is one of the most pressing in pediatrics. Hemosorption, hemodialysis and plasmapheresis has been successfully used in pediatric practice for a long time; however, the risk of their use may exceed expediency in some cases (for example, in case of moderate toxicity). Pediatricians have been always interested in non-invasive detoxification methods, in this context we have piloted Enterosgel, a new enterosorbent, in addition to infusion therapy, plasmapheresis, and in some cases as the unique detoxification therapy.
The comparative analysis of observation of two patient group (I group included the children received no Enterosgel (control) and II group included the children whose therapy involved this drug) showed that the improvement of the main clinical implications of disease (DRS) was diagnosed in the children received Enterosgel as a part of the complex therapy: in 75% of patients, the rash elements decreased in Day 3-4 after drug administration and Quicke’s edema disappeared in Day 2-3 of treatment. The positive effect of the Enterosgel therapy on the dyspeptic syndrome was observed: stool was normalizaed and nausea was terminated. In 49% of patients, disappearance of the pain abdominal syndrome was noted. It should be said that, in children under 2 years, the improvement in the decrement of the main disease manifestations was less appreciable and more delayed. This is explained by the morphofunctional dismaturity of the gastrointestinal tract in children of this age (enzymatic and topical immunologic deficiency, late onset of the formation of intestinal microbiology). At the same time, in the control group children received no Enterosgel, the improvement of clinical signs of DRS was less considerable and diagnosed only in 22% of patients. Disappearance of the DRS syndromes, pain abdominal and dyspeptic syndromes was delayed up to 7-8 Day of the complex therapy.
Thus, based on the study performed, one can conclude that application of Enterosgel in the complex therapy of childhood allergic diseases is pathogenetically proved and reasonable.